Navigation Links
Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
Date:11/14/2007

CHICAGO, Nov. 14 /PRNewswire-FirstCall/ -- The Female Health Company (Amex: FHC) today announced that it has received an order for four million FC Female Condoms from the Brazilian Ministry of Health. It is anticipated that shipments will begin in early calendar 2008.

Brazil is recognized by UNAIDS and other global public agencies for its highly effective HIV/AIDS prevention, care and treatment programs. The Company is pleased that Brazilian women will continue to have access to the FC Female Condom as a part of Brazil's outstanding and successful HIV/AIDS programming.

About The Female Health Company, Inc.

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. World-wide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy.

For more information about the Female Health Company, visit the Company's web site at http://www.femalehealth.com or http://www.femalecondom.org.

"Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plan and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.


'/>"/>
SOURCE The Female Health Company
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
6. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. Tone Deafness Explained, from the Harvard Health Letter
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
Breaking Medicine Technology:
(Date:4/22/2017)... New Freedom, PA (PRWEB) , ... April 22, ... ... of healthcare experience to his role as Vice President of Sales and Business ... direction of key GPO/IDN business partner engagements, business development, and strategic planning for ...
(Date:4/21/2017)... ... April 21, 2017 , ... Contrary to ... youth violence is declining—and at noteworthy rates. Between 2002 and 2014, Salas-Wright and ... involved in violence in the United States. The study, Trends in Fighting ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Dudnyk has announced ... emphasizes the agency’s conviction that the full potential of specialty and orphan brands can ... appreciated and aligned. , “The Unifying Effect is at the heart of a ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... 21, 2017 , ... Metrasens is honoured to have won ... most prestigious award for business success. The company has been recognized for ... grown by a total of 400% over the last six years. , Metrasens ...
Breaking Medicine News(10 mins):